Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX

The development of alloantibodies neutralising therapeutically administered factor (F) VIII/IX (inhibitors) is currently the most severe complication of the treatment of haemophilia. When persistent and at a high titre, inhibitors preclude the standard replacement treatment with FVIII/FIX concentrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocino, Angiola, Franchini, Massimo, Coppola, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406778/
https://www.ncbi.nlm.nih.gov/pubmed/28420167
http://dx.doi.org/10.3390/jcm6040046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406778/
https://www.ncbi.nlm.nih.gov/pubmed/28420167
http://dx.doi.org/10.3390/jcm6040046

Ejemplares similares